Skip to main content
. Author manuscript; available in PMC: 2021 Dec 28.
Published in final edited form as: Cancer Lett. 2020 Sep 11;495:76–88. doi: 10.1016/j.canlet.2020.09.004

Figure 3:

Figure 3:

VERU-111 may bypass P-gp efflux transporter in paclitaxel-resistant cells. (A) Comparison of P-gp expression on sensitive and resistant A549 cells by western blotting. (B) Rhodamine-123, a substrate for P-gp, had lower accumulation in resistant cells by using flow cytometry. (C) Verapamil, another positive substrate for P-gp, blocks the efflux transporter, and thereby increased accumulation of rhodamine-123 into the A549/TxR cells. (D-E) Comparison of rhodamine-123 accumulation in the presence of verapamil or VERU-111 in A549 and A549/TxR cell lines. The data is presented as mean ± SEM of triplicates and the unpaired t test with Welch’s correction or Dunnett multiple comparisons were performed for the statistical significance. ns = not significant, *p < 0.05, **p < 0.01 versus control or indicated.